Latest Inflammatory bowel disease Stories

LONDON, October 12, 2011 /PRNewswire/ -- - Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease - Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two...

PRINCETON, N.J., Oct. 11, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it relates to the development of SGX203 (oral beclomethasone dipropionate, or oral BDP) for the treatment of pediatric Crohn's disease. Comprised of pediatric gastroenterology thought leaders in the field of Crohn's...

HORSHAM, Pa., Sept. 29, 2011 /PRNewswire/ -- Season 10 American Idol contestant Casey Abrams has announced the top finalists in the national awareness campaign, IBD Icons, which celebrates the courage and persistence of those living with inflammatory bowel disease (IBD) and encourages them to never give in to their condition. Casey is asking Americans to vote for the two stories they find most inspiring at www.IBDIcons.com to help raise awareness and research funding for IBD. To view the...

Crohn disease (CD) and ulcerative colitis (UC) are the two most common forms of inflammatory bowel disease, affecting approximately 1 million people in the US. The severity of the symptoms and the frequency with which they recur varies widely among patients. Kenneth Smith and colleagues, at the University of Cambridge, United Kingdom, have now identified a gene expression profile that can divide patients with CD and UC into two otherwise undistinguishable subgroups -- those with a high...

SILVER SPRING, Md., Sept. 23, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Remicade reduces signs and symptoms of UC and induces and maintains clinical remission in these patients. UC is a type of inflammatory bowel...

HORSHAM, Pa., Sept. 23, 2011 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy. This marks the 16th approval of REMICADE® in the U.S. and the seventh for the anti-tumor necrosis factor (TNF)-alpha in the treatment of inflammatory bowel...

By using a mouse model of inflammation researchers at the University of Calgary have discovered a new class of molecules that can inhibit the recruitment of some white blood cells to sites of inflammation in the body. A provisional patent has been filed on these molecules by Innovates Calgary. When there is inflammation in the body, one of the primary defense mechanisms is the movement of white blood cells, known as neutrophils, from the bloodstream into the infected tissue. Neutrophils...

Scientists have identified a surprising new role for a new type of T cell in the immune system: some of them can be activated by nerves to make a neurotransmitter (acetylcholine) that blocks inflammation. The discovery of these T cells is novel and suggests that it may be possible to treat inflammation and autoimmune diseases by targeting the nerves and the T cells. The study was published this week in Science. "The discovery that 2 percent of T cells can make acetylcholine under the...

Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition. The aberrant immune response found in IBD is prompted by different cytokines – small signaling proteins secreted by various cells, including immune cells –...

UPPER SADDLE RIVER, N.J., Aug. 22, 2011 /PRNewswire-iReach/ -- WellApps, INC. announced today the latest release of GI Monitor, the leading (IBD) Crohn's and Colitis mobile disease management platform. The new release adds the ability for users to Socialize in real-time as they track their conditions, making GI Monitor one of the largest global social destinations for (IBD) Inflammatory Bowel Disease patients. Brett Shamosh, 20-year Ulcerative Colitis patient and Co-Founder of WellApps...